Almac Group Plans for £80 million expansion in Northern Ireland

Specifications:

Name:

Almac Group Plans for £80 million expansion in Northern Ireland

Location:

Ireland

Company:

Almac Group

Estimated Cost:

£80 million

Source:

https://www.almacgroup.com/

Introduction:

The Almac Group has announced an £80 million investment programme to build new extensive manufacturing, production and diagnostic laboratory facilities at its Global Headquarters in Craigavon, Northern Ireland.

Festaures:

The construction of these two significant facilities will create over 550 jobs locally, spanning a range of lab and non-lab-based roles, with recruitment already commenced for some positions.  This is part of the company’s international recruitment drive which is expected to create 1,000 jobs in Northern Ireland over three years.

The first of these two major projects is a 100,000ft state-of-the-art multi-product Good Manufacturing Practice (GMP) facility for Almac Pharma Services. This Centre of Excellence for manufacturing will house a custom designed dispensary area, multiple production suites, process equipment wash facilities and a lineside warehouse for ambient, refrigerated and frozen storage.  The new facility will primarily support solid oral dose products, complementing Almac’s existing capabilities in this area.

The facility, which will be operational from Q3 2024, will expand Almac Pharma Services’ existing manufacturing capabilities and offers additional capacity for further strategic production contracts.  The high-specification production suites have been designed with flexibility and a wide range of uses in mind which offers opportunities for clients to install bespoke technology specific to their individual needs.

The second project is a 40,000 ft four-storey diagnostic development and manufacturing centre for Almac Diagnostic Services which will be completed by Q1 2024. The new facility will enable Almac Diagnostic Services to expand its assay development offering and to manufacture and distribute Companion Diagnostic (CDx) kits on a commercial scale to support growing client demand.

This expansion will enhance Almac’s existing early phase biomarker development capabilities through to assay development and deployment in clinical trials, cementing the company’s position in the market as a fully resourced partner of choice to pharma companies for manufacturing and commercialisation of companion diagnostics.